Disease outcomes and effect of treatment on brain function in patients with primary CNS Lymphoma undergoing high dose chemotherapy.
- Conditions
- Health Condition 1: C851- Unspecified B-cell lymphoma
- Registration Number
- CTRI/2020/12/030005
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients with histologically proven PCNSL and planned for ASCT
2. Age > 18 years and less than 65 years
3. ECOG PS <4
4.Adequate bone marrow function with absolute leukocytes > 2000/mm3, neutrophil count (ANC) > 1000/mm3, hemoglobin > 8 g/dl and platelets > 100 000/mm3
5.Adequate liver function with Serum SGOT/AST or SGPT/ALT < 3.0 X Upper Limit of Normal ULN ; bilirubin < 1.5 X LNS
6. Creatinine clearance > 60 ml/min.
7.Adequate cardiac function (LVEF more than 45%)
8.Adequate lung function (DLCO more than 50%)
9. Able to understand and sign informed consent
Chemo-refractory disease
2.HIV infection
3.Active hepatitis B or C
4.Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free SurvivalTimepoint: 2 years
- Secondary Outcome Measures
Name Time Method Grade 3 or more side effects <br/ ><br>Timepoint: 2 years;Neuro-cognitive assessmentTimepoint: 2 years;Overall survivalTimepoint: 2 year;Quality of lifeTimepoint: 2 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.